MedWatch

GN CEO on job security: "It's a board decision"

After the company's former head of research and development was let go earlier this month, CEO at GN Hearing Gitte Aabo is next in line to take full responsibility for current developments. Whether she will survive more delays and downgrades is up to the board, she says.

Photo: GN Hearing / PR

October 2021 won't be a month that is forgotten quickly at GN Hearing.

At the beginning of the month, GN Hearing's head of research and development Pär Thureson was let go as a consequence of the delays of two key product launches and a subsequent 2021 guidance downgrade.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs